LeafBio Submits Investigational New Drug Application for Lead Product Candidate ZMapp™ for the Treatment of Ebola Virus Infection

Toronto, ON February 6, 2015 Defyrus Inc. announced today that its licensee LeafBio Inc. (Mapp Biopharmaceutical Inc. commercialization arm; "LeafBio") of San Diego, USA has submitted an Investigational New Drug application (IND) for ZMapp™ to the United States Food and Drug Adminsitration.

Defyrus and LeafBio are both private biopharmaceutical companies that are working collaboratively on the advance development of therapies for viral hemorraghic fevers, specifically Ebola virus, for which no approved therapies or vaccine exist. ZMapp™ is a mixture of three monoclonal antibodies (mAb) designed to specifically recognize and bind to Ebola virus surface glycoproteins.

"Today's announcement highlights the successful private-public partnership model for our drug development", said John Hyshka, Chairman of Defyrus, "The Public Health Agency of Canada (PHAC) in Winnipeg pioneered two of these mAbs and licensed the commercial rights to us. In a similar manner, the third key mAb was pioneered within US gov't and licensed to LeafBio. To create a "one-stop-shop" for the development of ZMapp™, last year Defyrus sublicensed its technology to LeafBio who is now the commercial lead. This IND submission shows that cooperation leads to better, more cost effective and faster drug development".

About Defyrus: we are a private, life sciences biodefence company that collaborates with public health & biodefense R&D partners in the United States, European Union, Canada and Asia to develop and manufacture broad spectrum anti-viral drugs, MAbs and vaccines as effective medical countermeasures to treat viral-based diseases worldwide.

www.defyrus.com

ZMapp™ is a trademark of LeafBio Inc.